Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-one research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $66.24.
Several research analysts have commented on the stock. UBS Group reissued a "buy" rating and set a $70.00 price target on shares of Definium Therapeutics in a research note on Tuesday, September 15th. Canaccord Genuity Group set a $78.00 price target on Definium Therapeutics and gave the stock a "buy" rating in a research note on Tuesday, September 15th. HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. JPMorgan Chase & Co. assumed coverage on Definium Therapeutics in a research report on Friday, October 9th. They issued an "overweight" rating and a $84.00 price objective on the stock. Finally, Royal Bank Of Canada increased their target price on Definium Therapeutics from $66.00 to $70.00 and gave the company an "outperform" rating in a research report on Tuesday, November 10th.
Check Out Our Latest Stock Analysis on Definium Therapeutics
Insiders Place Their Bets
In other news, CFO Brandi Roberts sold 3,377 shares of the company's stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the transaction, the chief financial officer directly owned 394,528 shares in the company, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the business's stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the sale, the chief executive officer directly owned 2,213,090 shares of the company's stock, valued at approximately $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,098 shares of company stock worth $2,626,115 in the last 90 days. 2.40% of the stock is owned by insiders.
Institutional Trading of Definium Therapeutics
A number of hedge funds have recently added to or reduced their stakes in DFTX. Pinnacle Wealth Planning Services Inc. boosted its position in Definium Therapeutics by 2,928.0% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company's stock valued at $29,000 after purchasing an additional 732 shares in the last quarter. Bessemer Group Inc. acquired a new position in shares of Definium Therapeutics in the third quarter worth about $42,000. Nykredit A S acquired a new position in shares of Definium Therapeutics during the 2nd quarter worth approximately $45,000. GAMMA Investing LLC raised its position in shares of Definium Therapeutics by 28.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,555 shares of the company's stock worth $59,000 after purchasing an additional 343 shares during the last quarter. Finally, Allworth Financial LP acquired a new stake in shares of Definium Therapeutics in the second quarter worth approximately $110,000. 27.91% of the stock is owned by hedge funds and other institutional investors.
Definium Therapeutics Price Performance
DFTX opened at $32.08 on Monday. Definium Therapeutics has a twelve month low of $10.46 and a twelve month high of $49.70. The company's 50-day moving average price is $36.07 and its two-hundred day moving average price is $30.38. The stock has a market cap of $4.39 billion, a price-to-earnings ratio of -10.32 and a beta of 2.23. The company has a quick ratio of 15.53, a current ratio of 15.53 and a debt-to-equity ratio of 0.04.
Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.09. As a group, equities analysts expect that Definium Therapeutics will post -2.94 earnings per share for the current year.
About Definium Therapeutics
(
Get Free Report)
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Definium Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definium Therapeutics wasn't on the list.
While Definium Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.